Results 191 to 200 of about 7,910 (224)
Some of the next articles are maybe not open access.
Drugs, 1998
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. Adenosine diphosphate (ADP)-induced platelet aggregation returns to near-baseline levels within 4 to 8 hours after ...
Karen L. Goa, Karen J. McClellan
openaire +3 more sources
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. Adenosine diphosphate (ADP)-induced platelet aggregation returns to near-baseline levels within 4 to 8 hours after ...
Karen L. Goa, Karen J. McClellan
openaire +3 more sources
The Effect of Tirofiban on Microvascular Thrombosis: Crush Model
Plastic and Reconstructive Surgery, 2005Microvascular anastomotic thrombosis is a significant clinical problem, particularly in crush and avulsion injuries. Platelet deposition plays a particularly important role in the initiation and propagation of microvascular thrombosis, whereas thrombin has little effect in the acute phase of thrombus formation.
Carlos L. Farias +4 more
openaire +3 more sources
Synthesis and biological evaluation of PEG-tirofiban conjugates
Bioorganic & Medicinal Chemistry Letters, 2008We have conjugated tirofiban, an antagonist of the GPIIb/IIIa integrin receptor, to PEG, and shown that these polymers effectively inhibit platelet aggregation. This inhibition decreased with the size of the polymer. Our goal was to develop new cryoprotective agents to store frozen platelets.
Jean-Pierre Cazenave +3 more
openaire +3 more sources
Vertebrobasilar Thrombolysis with Intravenous Tirofiban: Case Report
Journal of Thrombosis and Thrombolysis, 2002The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage.
Michael L. McGarvey +5 more
openaire +3 more sources
Tirofiban-induced diffuse alveolar haemorrhage
BMJ Case ReportsA middle-aged man presented with inferior wall ST-elevation myocardial infarction and underwent primary percutaneous coronary intervention with tirofiban administered due to extensive thrombus. He developed sudden-onset dyspnoea, bilateral crepitations, haemoptysis, desaturation and hypotension an hour after starting tirofiban infusion.
Bryan, Sebastian +2 more
openaire +2 more sources
The Role of Tirofiban in the Management of Coronary Artery Disease
Cardiovascular & Hematological Disorders-Drug Targets, 2008Glycoprotein IIb/IIIa receptor antagonists are potent antiplatelet agents by inhibiting the final common pathway of platelet aggregation. Tirofiban binds specifically to the glycoprotein IIb/IIIa receptor resulting in immediate and extensive inhibition of platelets.
Craig P. Juergens, Julian P Winter
openaire +3 more sources
Tirofiban: a breakthrough in treating unstable angina
Inpharma Weekly, 1997Adding the glycoprotein IIb/IIIa receptor antagonist tirofiban # to standard treatment for patients with unstable angina pectoris and non-Q-wave myocardial infarction (MI) can significantly reduce ischaemic complications, note researchers from the PRISM * and PRISM-plus *
openaire +2 more sources
Tirofiban in Coronary Intervention—The RESTORE Trial
1999Atheromatous plaque rupture, platelet activation with consequent thrombus formation and impairment of coronary arterial blood flow is a common theme in acute coronary syndromes (ACS) (1–4). The importance of antiplatelet therapy in the treatment of acute myocardial infarction (MI) was amply demonstrated in the second International Study of Infarct ...
Mahomed Y. Salame +2 more
openaire +2 more sources